title: Drug consumption and the risk of microscopic colitis.
abstract: BACKGROUND
  Microscopic colitis is a rare disease of unknown etiology. It has been described that some drugs could cause or worsen the disease; however, the scientific evidence is limited.
  
  
  OBJECTIVE
  To investigate the possible association of chronic drug consumption with microscopic colitis.
  
  
  METHODS
  This was a case-control study in which groups of cases were: Group 1-39 patients with collagenous colitis; Group 2-39 patients with lymphocytic colitis; and Group 3-52 patients with chronic watery diarrhea of functional characteristics. 103 subjects formed the control group. At diagnosis, a drug consumption history of at least 2-wk duration was registered. An age- and sex-adjusted logistic regression analysis was used, and the odds ratio (OR, 95% CI) was calculated.
  
  
  RESULTS
  Drug consumption was more frequent in lymphocytic colitis than in the control group (92.3%vs 76.3%, P < 0.05). The mean daily number of drugs by person was also higher in lymphocytic colitis (3.79 +/- 0.44 vs 2.13 +/- 0.22, P= 0.04). The following associations as compared with the control group were observed: Group 1-Consumption of NSAIDs (46.2%vs 23%, OR 2.9, 1.3-6.4), selective serotonin reuptake inhibitors (SSRIs) (18%vs 1%, OR 21, 2.5-177), specifically, sertraline (15.4%vs 0%, P < 0.0005); Group 2-SSRIs (28%vs 1%, OR 37.7, 4.7-304), beta-blockers (13 vs 3%, OR 4.79, 1.04-20), statins (13%vs 3%, OR 4.6, 1.04-20), biphosphonates (8%vs 0%, P= 0.022); Group 3-SSRIs (15%vs 1%, OR 16.2, 2-135), statins (11.5%vs 3%, OR 5.4, 1.2-24). As compared with the chronic diarrhea group, a significant association with the usage of sertraline in LC (P= 0.005) and a trend for NSAIDs in CC (P= 0.057) were found.
  
  
  CONCLUSIONS
  Drug consumption increases the risk of microscopic colitis. Some drugs might be trigger factors of colonic inflammation in predisposed hosts, and others might only worsen self-evolving microscopic colitis.
authors.affiliation: Department of Gastroenterology, Hospital Universitari Mutua Terrassa, Barcelona, Spain.
authors.forename: Fernando
authors.initials: F
authors.lastname: Fernández-Bañares
authors.forename: Maria
authors.initials: M
authors.lastname: Esteve
authors.forename: Jorge C
authors.initials: JC
authors.lastname: Espinós
authors.forename: Mercé
authors.initials: M
authors.lastname: Rosinach
authors.forename: Montserrat
authors.initials: M
authors.lastname: Forné
authors.forename: Antonio
authors.initials: A
authors.lastname: Salas
authors.forename: Josep Maria
authors.initials: JM
authors.lastname: Viver
mesh_terms: D000368:Aged; D046729:Colitis, Collagenous / Q000139:chemically induced* / Q000175:diagnosis / Q000453:epidemiology; D046730:Colitis, Lymphocytic / Q000139:chemically induced* / Q000175:diagnosis / Q000453:epidemiology; D003113:Colonoscopy; D064420:Drug-Related Side Effects and Adverse Reactions; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D012189:Retrospective Studies; D012307:Risk Factors; D011795:Surveys and Questionnaires